The endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitors (TKIs) sunitinib and pazopanib are approved for the vast majority of patients with untreated advanced RCC and are the standard of care in this setting (6, 7). This evidence concerns the gene KDR and renal cell adenocarcinoma.